3SBio Inc (83B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 3SBio Inc (83B) has a cash flow conversion efficiency ratio of 0.037x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€592.24 Million ≈ $692.39 Million USD) by net assets (€15.96 Billion ≈ $18.66 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
3SBio Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how 3SBio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does 3SBio Inc carry for a breakdown of total debt and financial obligations.
3SBio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 3SBio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lien Viet Post Joint Stock Commercial Bank
VN:LPB
|
0.284x |
|
Pharmaron Beijing Co Ltd
SHE:300759
|
0.068x |
|
Reece Ltd
AU:REH
|
0.054x |
|
Sandfire Resources Ltd
AU:SFR
|
0.294x |
|
E Ink Holdings
TWO:8069
|
0.059x |
|
Zhejiang CFMoto Power Co Ltd
SHG:603129
|
0.109x |
|
Ringkjoebing Landbobank A/S
CO:RILBA
|
0.002x |
|
Bank of Ayudhya Public Company Limited
F:NVAU
|
0.097x |
Annual Cash Flow Conversion Efficiency for 3SBio Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of 3SBio Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see 83B company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €18.04 Billion ≈ $21.09 Billion |
€3.20 Billion ≈ $3.74 Billion |
0.177x | +40.72% |
| 2023-12-31 | €16.51 Billion ≈ $19.31 Billion |
€2.08 Billion ≈ $2.44 Billion |
0.126x | -10.91% |
| 2022-12-31 | €15.40 Billion ≈ $18.00 Billion |
€2.18 Billion ≈ $2.55 Billion |
0.142x | +31.48% |
| 2021-12-31 | €14.66 Billion ≈ $17.14 Billion |
€1.58 Billion ≈ $1.85 Billion |
0.108x | +4.86% |
| 2020-12-31 | €13.09 Billion ≈ $15.31 Billion |
€1.34 Billion ≈ $1.57 Billion |
0.103x | -43.64% |
| 2019-12-31 | €10.36 Billion ≈ $12.11 Billion |
€1.89 Billion ≈ $2.21 Billion |
0.182x | +41.09% |
| 2018-12-31 | €8.91 Billion ≈ $10.41 Billion |
€1.15 Billion ≈ $1.34 Billion |
0.129x | -8.27% |
| 2017-12-31 | €7.63 Billion ≈ $8.92 Billion |
€1.07 Billion ≈ $1.26 Billion |
0.141x | -5.15% |
| 2016-12-31 | €6.77 Billion ≈ $7.91 Billion |
€1.00 Billion ≈ $1.17 Billion |
0.148x | -- |
About 3SBio Inc
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER… Read more